These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 26233310)

  • 1. Involvement of polyphosphate kinase in virulence and stress tolerance of uropathogenic Proteus mirabilis.
    Peng L; Jiang Q; Pan JY; Deng C; Yu JY; Wu XM; Huang SH; Deng XY
    Med Microbiol Immunol; 2016 Apr; 205(2):97-109. PubMed ID: 26233310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Requirement of MrpH for mannose-resistant Proteus-like fimbria-mediated hemagglutination by Proteus mirabilis.
    Li X; Johnson DE; Mobley HL
    Infect Immun; 1999 Jun; 67(6):2822-33. PubMed ID: 10338487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete genome sequence of uropathogenic Proteus mirabilis, a master of both adherence and motility.
    Pearson MM; Sebaihia M; Churcher C; Quail MA; Seshasayee AS; Luscombe NM; Abdellah Z; Arrosmith C; Atkin B; Chillingworth T; Hauser H; Jagels K; Moule S; Mungall K; Norbertczak H; Rabbinowitsch E; Walker D; Whithead S; Thomson NR; Rather PN; Parkhill J; Mobley HL
    J Bacteriol; 2008 Jun; 190(11):4027-37. PubMed ID: 18375554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. cAMP receptor protein regulates mouse colonization, motility, fimbria-mediated adhesion, and stress tolerance in uropathogenic Proteus mirabilis.
    Tsai YL; Chien HF; Huang KT; Lin WY; Liaw SJ
    Sci Rep; 2017 Aug; 7(1):7282. PubMed ID: 28779108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mannose-resistant Proteus-like fimbriae are produced by most Proteus mirabilis strains infecting the urinary tract, dictate the in vivo localization of bacteria, and contribute to biofilm formation.
    Jansen AM; Lockatell V; Johnson DE; Mobley HL
    Infect Immun; 2004 Dec; 72(12):7294-305. PubMed ID: 15557655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repression of bacterial motility by a novel fimbrial gene product.
    Li X; Rasko DA; Lockatell CV; Johnson DE; Mobley HL
    EMBO J; 2001 Sep; 20(17):4854-62. PubMed ID: 11532949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of virulence determinants in uropathogenic Proteus mirabilis using signature-tagged mutagenesis.
    Himpsl SD; Lockatell CV; Hebel JR; Johnson DE; Mobley HLT
    J Med Microbiol; 2008 Sep; 57(Pt 9):1068-1078. PubMed ID: 18719175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteus mirabilis and Urinary Tract Infections.
    Schaffer JN; Pearson MM
    Microbiol Spectr; 2015 Oct; 3(5):. PubMed ID: 26542036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of protease and rpoN-associated genes of uropathogenic Proteus mirabilis by negative selection in a mouse model of ascending urinary tract infection.
    Zhao H; Li X; Johnson DE; Mobley HLT
    Microbiology (Reading); 1999 Jan; 145 ( Pt 1)():185-195. PubMed ID: 10206698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteus mirabilis uroepithelial cell adhesin (UCA) fimbria plays a role in the colonization of the urinary tract.
    Pellegrino R; Scavone P; Umpiérrez A; Maskell DJ; Zunino P
    Pathog Dis; 2013 Mar; 67(2):104-7. PubMed ID: 23620155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Copper affects virulence and diverse phenotypes of uropathogenic Proteus mirabilis.
    Huang WS; Lee YJ; Wang L; Chen HH; Chao YJ; Cheng V; Liaw SJ
    J Microbiol Immunol Infect; 2024 Jun; 57(3):385-395. PubMed ID: 38453541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New aspects of RpoE in uropathogenic Proteus mirabilis.
    Liu MC; Kuo KT; Chien HF; Tsai YL; Liaw SJ
    Infect Immun; 2015 Mar; 83(3):966-77. PubMed ID: 25547796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From Catheter to Kidney Stone: The Uropathogenic Lifestyle of Proteus mirabilis.
    Norsworthy AN; Pearson MM
    Trends Microbiol; 2017 Apr; 25(4):304-315. PubMed ID: 28017513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteus mirabilis fimbriae: construction of an isogenic pmfA mutant and analysis of virulence in a CBA mouse model of ascending urinary tract infection.
    Massad G; Lockatell CV; Johnson DE; Mobley HL
    Infect Immun; 1994 Feb; 62(2):536-42. PubMed ID: 7905463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New aspects of the role of MR/P fimbriae in Proteus mirabilis urinary tract infection.
    Zunino P; Geymonat L; Allen AG; Preston A; Sosa V; Maskell DJ
    FEMS Immunol Med Microbiol; 2001 Aug; 31(2):113-20. PubMed ID: 11549418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo phase variation of MR/P fimbrial gene expression in Proteus mirabilis infecting the urinary tract.
    Zhao H; Li X; Johnson DE; Blomfield I; Mobley HL
    Mol Microbiol; 1997 Mar; 23(5):1009-19. PubMed ID: 9076737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A CpxR-Regulated
    Chen HH; Chang CC; Yuan YH; Liaw SJ
    Infect Immun; 2020 Jun; 88(7):. PubMed ID: 32284373
    [No Abstract]   [Full Text] [Related]  

  • 18. Aggregative adherence of uropathogenic Proteus mirabilis to cultured epithelial cells.
    Rocha SP; Elias WP; Cianciarullo AM; Menezes MA; Nara JM; Piazza RM; Silva MR; Moreira CG; Pelayo JS
    FEMS Immunol Med Microbiol; 2007 Nov; 51(2):319-26. PubMed ID: 17714491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The high-affinity phosphate transporter Pst is a virulence factor for Proteus mirabilis during complicated urinary tract infection.
    Jacobsen SM; Lane MC; Harro JM; Shirtliff ME; Mobley HL
    FEMS Immunol Med Microbiol; 2008 Mar; 52(2):180-93. PubMed ID: 18194341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The type III secretion system of Proteus mirabilis HI4320 does not contribute to virulence in the mouse model of ascending urinary tract infection.
    Pearson MM; Mobley HLT
    J Med Microbiol; 2007 Oct; 56(Pt 10):1277-1283. PubMed ID: 17893161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.